The biotech firm’s second-quarter loss exceeded analyst estimates by $0.21 per share, signaling higher costs or lower revenue.
Mind Medicine reported a second-quarter GAAP loss of $0.71 per share, missing expectations by $0.21. The wider-than-anticipated deficit reflects increased operational expenses or weaker-than-projected revenue streams.
Analysts had forecasted a narrower loss for the period, with consensus estimates closer to $0.50 per share. The company’s prior quarter had shown a smaller loss, highlighting a deterioration in financial performance.
Shares may face pressure as investors reassess growth projections amid the deeper loss.